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Although metastatic breast cancer (MBC) is considered a
chemosensitive tumour, its palliative treatment remains a chal-
lenge. Drug associations are usually employed as first line treat-
ment, despite the controversy (Winer et al, 2001) as to whether
combination chemotherapy does or does not provide greater anti-
tumour effect than single agents used at appropriate dose levels
(Sledge et al, 1997; Bishop et al, 1999; Nabholtz et al, 1999). 
Anthracycline-containing regimens, administered for 6–8
courses, are probably the first choice therapy in patients who have
not received an anthracycline as adjuvant therapy. The association
of doxorubicin or epirubicin with 5-fluorouracil and cyclophos-
phamide (FAC or FEC regimens) produces a higher response rate
(RR) and longer time to progression than CMF-like regimens
(Fossati et al, 1998), and a survival advantage is confirmed in the
adjuvant setting (Coombes et al, 1996; Levine et al, 1998). From
several trials on MBC, anthracycline-containing regimens produce
a RR of about 65% (with a 16% rate of complete responses), a
progression-free survival of 11.5 months and an overall survival of
21 months (Rahman et al, 1999). 
Ways of ameliorating the treatment of MBC have included
increasing the drug dose-intensity, maintenance therapy and use of
new drugs. 
No clear advantage has been obtained from doubling the anthra-
cycline dose intensity within the FEC regimen (Biganzoli and
Piccart, 1997; Riccardi et al, 2000). 
The relevance of continuing long-lasting combination chemo-
therapy following FEC, as a maintenance, is also largely unsettled.
This approach has increased the time to progression, but the survival
advantage was not significant and toxicity was increased (Muss et al,
1991; Falkson et al, 1998). 
New treatment opportunities to be explored come from
the availability of new drugs that are both highly effective
and not cross-resistant with the anthracyclines. Taxanes have
substantial activity in previously treated patients (Holmes et al,
1991; Reichman et al, 1993), including a 30–50% RR in anthra-
cycline-resistant disease (Gehl et al, 1996; Nabholtz et al, 1996;
Pivot et al, 1999; Rivera et al, 2000).
Combined with doxorubicin, paclitaxel produces a higher RR
than either paclitaxel or doxorubicin alone (Sledge et al, 1997;
Pouillart et al, 1999), but myelosuppressive and mucosal toxici-
ties are substantially increased. This happens particularly when
paclitaxel is administered shortly before the anthracycline,
because paclitaxel lowers doxorubicin elimination, especially with
long-lasting infusions (Conte et al, 1997; Venturini et al, 2000). 
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Summary Sequential administration of the association of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel could be
better tolerated than the association of an anthracycline and paclitaxel while having a similar antitumour effect. 69 patients with advanced
breast cancer previously untreated with anthracyclines or paclitaxel entered a phase II multicentre study in which FEC was followed by
paclitaxel. Both regimens were administered 4 times every 21 days. The median follow-up is 20 months and 38/69 patients have died. Grade
III–IV toxicity was acceptable. Leukopenia occurred in 26% of patients, thrombocytopenia in 2% and anaemia in 4%. One patient had
reversible heart failure during FEC therapy. Peripheral neuropathy and arthralgia-myalgia occurred in 9% and 4% of patients, respectively and
one patient had respiratory hypersensitivity during paclitaxel treatment. 9 patients did not complete therapy because of: treatment refusal 
(n = 1), cardiac toxicity (n = 1), early death during FEC chemotherapy (n = 1), major protocol violations (n = 4), hypersensitivity reaction (n =
1) and early death during paclitaxel chemotherapy (n = 1). The overall response rate was 65% (95% CI = 53–76), and 7% of patients had
stable disease. Therapy was defined as having failed in 28% of patients because they were not evaluable (13%) or had progressive disease
(15%). The median time to progression and survival are 13.2 and 23.5 months, respectively. Sequential FEC-paclitaxel is a suitable strategy
for patients with metastatic breast cancer who have not been previously treated with anthracyclines and/or taxanes. In fact, it avoids major
haematologic toxicity and has a good antitumour effect. © 2001 Cancer Research Campaign http://www.bjcancer.com
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doi: 10.1054/ bjoc.2001.1897, available online at http://www.idealibrary.com on  http://www.bjcancer.comAnother way of treatment could be sequencing FEC with
taxanes as first-line therapy. Antitumour advantages from FEC
could be enhanced by the addition of a sequential non-cross-resis-
tant drug for a short period. Avoiding combination chemotherapy
is also expected to lower overall toxicity. 
We used an integrated treatment with sequential FEC and pacli-
taxel in a multicenter phase II study as first or second line treat-
ment in MBC patients previously untreated with anthracyclines or
taxanes as adjuvant therapy (Protocol PV BC 97/01). 
PATIENTS AND METHODS 
Between January, 1998, and July, 1999, a phase II multicentre
study (PV BC 97/01) enrolled 69 consecutive patients with MBC
who had not previously received anthracyclines or taxanes as adju-
vant therapy or as first-line therapy for metastatic disease. Patients
were treated with sequentially administered FEC and paclitaxel
therapy. 
The study was approved by the Clinical Research Review Board
of the Department of Internal Medicine of University of Pavia and
IRCCS Policlinico S. Matteo, and written informed consent was
obtained from each patient. 
Eligibility and exclusion criteria 
Patients had progressive MBC and had not previously received
anthracyclines or taxanes. 
Eligibility criteria were: histologic or cytologic proof of primary
breast cancer; presence of at least one metastatic lesion bidimen-
sionally measurable by physical examination and/or radiologic
means; age between 18 and 70 years; performance status (PS) ≤ 2
(World Health Organization, WHO, scale); life expectancy > 6
months; normal blood counts and biochemistry (absolute granulo-
cyte, WBC, count > 2.0 ´ 109 l–1, platelets, PLT, count > 100 ´ 109
l–1, bilirubin < 34 mmol l–1, creatinine < 106 mmol l–1) and normal
cardiac function (i.e., normal ECG and 2-dimensional echocardio-
graphy showing a left ventricular ejection fraction, LVEF, > 50%). 
Exclusion criteria included pregnancy or lactation, childbearing
potential without adequate contraception, preexisting grade II or
higher motosensorial neurotoxicity, and concomitant treatment
with other experimental drugs. 
Drop-out criteria were WHO grade IV non-haematologic toxi-
city, symptomatic heart failure or LVEF reduction to < 50% of pre-
treatment value, refusal to continue participation in the study, loss
to follow-up, or major treatment violations. All these patients were
considered as non-responders, so that results are described on an
intention-to-treat basis. 
Treatment 
Patients received 4 courses of FEC (mg m–2: 5-fluorouracil 600,
epirubicin 60, cyclophosphamide 600) chemotherapy followed
by 4 courses of paclitaxel (175 mg m–2 as a 3 h i.v. infusion)
chemotherapy. Before paclitaxel, patients were premedicated
with prednisone (125 mg p.o. 12 and 6 h before paclitaxel),
ranitidine (300 mg p.o. 12 h and 300 mg i.v. 1 h before
paclitaxel) and diphenhydramine (10 mg i.v. just before pacli-
taxel). Both FEC and paclitaxel were administered every 21
days. 
Ondansentron or granisetron were used as antiemetics.
Patients with leukopenia (WBC ≤ 1.0 ´ 109 l–1) received oral
ciprofloxacin (500 mg twice a day) as antibiotic prophylaxis. If
the patient developed fever > 38.0˚C and neutropenia, they were
hospitalized and treated with i.v. netilmicin (2 mg kg–1) and
piperacillin (2 g) twice a day. If fever persisted beyond 6
days despite antibiotic treatment, i.v. fluconazol (200 mg twice
a day) was added. No prophylactic use of haematopoietic
growth factors was planned. However, if granulocytes were
< 0.5 ´ 109 l–1 on day 14, the patients were given subcutaneous
granulocyte colony-stimulating factor (G-CSF, 5 mg kg–1
day–1). Clodronate (600–900 mg week–1) or pamidronate
(90 mg/3 weeks) were given by i.v. infusion to patients with
bone lesions. 
Toxic effects of treatments were assessed according to WHO
criteria. 
Treatment monitoring 
Pre-treatment evaluation included a complete medical history,
clinical examination, complete blood counts and biochemistry,
ECG, chest X-ray, liver ultrasounds, bone scan and, if indicated,
computed tomography. Bone marrow aspiration and/or biopsy
were performed when blood cell counts were unexplainably
abnormal. 
Before each FEC or paclitaxel course, physical examination
was performed. Blood counts were obtained on days 10, 14 and
21 of each course. Before starting the subsequent drug adminis-
tration (i.e. on day 21 of each chemotherapy course), guidelines
were given for delaying treatment or reducing its dosage. If
platelets were < 100 ´ 109 l–1 and/or WBC < 3.0´ 109 l–1, a week’s
delay in resuming chemotherapy had to be observed. If the PLT or
WBC count was still low after this delay, all drug dosages were
halved. 
Following the fourth course of FEC and following the fourth
course of paclitaxel, the whole pre-treatment evaluation was
repeated to assess response to therapy. 
Criteria for tumour response and toxicity 
Tumour responses and toxic effects of treatment were assessed,
using WHO criteria, after 4 courses of FEC and again after 4
courses of paclitaxel. For those patients with only assessable bone
metastases, the UICC criteria for skeletal disease were used. As
defined by these criteria, partial or complete responses require
recalcification of lytic lesions while disease progression is
enlargement of an already existing lesions or the appearance of
new lesions. 
The choice of evaluating response following the fourth course
of FEC was based on our previous data which indicated that
response to FEC was similar following 3 and 6 courses of this
regimen (Riccardi et al, 2000). 
Duration of response was taken to be the period from the end of
successful induction therapy until relapse, and surviving patients
who had not relapsed during the follow-up were censored from the
data analysis. Patients who died before relapse were considered as
events. 
Time to progression (TTP) was defined as the time from starting
treatment to when progression of the disease was first docu-
mented. 
Survival was the time from starting treatment to death. 
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This phase II, non-randomized, open-labelled study, required
about 70 patients to be enrolled, as calculated by Gehan’s method
accounting for the principal end-point, i.e. response to treatment,
in order for results to be statistically meaningful. The expected
complete or partial RR was 60%, with 5% false positives and a
power of 90%. The planned study duration was 24 months,
providing a median 12 month-follow-up period after treatment
discontinuation. 
The Kaplan–Meier methodology was used for plotting response
duration, TTP and overall survival. 
RESULTS 
The main clinical characteristics of the 69 recruited patients are
reported in Table 1. 
Median age was 54 (range: 34–70) years. Of the 69 patients, 27
had received adjuvant hormone therapy and 30 adjuvant CMF
chemotherapy. 59 patients had single or multiple visceral involve-
ment. 2 patients had bone disease only. 
A total of 488 chemotherapy courses (88% of those
planned) were administered, namely 264 of FEC (96% of
those planned) and 224 of paclitaxel (81% of those planned). The
mean number of delivered courses was 3.8/patient for FEC and
3.3/patient for paclitaxel treatment. A number of courses were not
administered because 9 patients did not complete therapy, for the
reasons reported below. 
At time of this analysis (July 2000), the median follow-up of all
recruited patients is 20 (range: 2–32) months and 38 of 69 (55%)
patients have died. 
Toxicity 
Grade III–IV haematologic and non-haematologic toxicities
during FEC and paclitaxel treatments, as evaluable in 60 of 69
patients, are detailed in Table 2. Both were acceptable. 
As expected, epirubicin was more toxic than paclitaxel in terms
of haematologic, gastrointestinal, and cardiac side effects, while
paclitaxel induced more neurotoxicity (mainly sensory) and
arthralgia/myalgia. 
Over the whole sequential treatment, leukopenia occurred in
26% of patients (with no febrile episodes), thrombocytopenia in
2% and anaemia in 4%. Of the courses of FEC and paclitaxel
administered, 93% of the former and 91% of the latter were deliv-
ered without the need for dose reductions or delay, and did not
require the use of G-CSF. 
Alopecia was almost universal. Mucositis (stomatitis and/or
diarrhea) occurred in 2% of patients. During FEC therapy,
symptomatic cardiotoxicity occurred in one patient, who devel-
oped reversible heart failure, and LVEF decreased by > 20%
in 2 other patients. During paclitaxel treatment, peripheral
neuropathy (tingling, numbness and paraesthesia) occurred in
9% of patients and arthralgia and/or myalgia in 4%. One patient
had a respiratory hypersensitivity reaction during paclitaxel
therapy. 
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Table 1 Characteristics of patients with metastatic breast cancer who were
treated with first-line sequential 5-fluorouracil + epirubicin +
cyclophosphamide (FEC) and paclitaxel therapy 
No. of entered patients 69 
Age, years 
Median 54 
Range 34–70 
WHO performance status 
0 37 
1 22 
2 10 
DFI, months 
Median 36 
Range 0–216 
Prior radiotherapy 10 
Prior hormotherapy 27 
Prior adiuvant chemotherapy (CMF) 30 
Sites of disease 
Visceral organs ± bone ± soft tissue 59 
visceral organs ≤ 2 30 
visceral organs > 2 29 
Bone ± soft tissue 6 
Soft tissue ± locoregional 4 
No of metastatic sites 
1 37 
2 19 
³3 13 
Hormone receptor status 
positive 33 
negative 19 
unknown 17 
DFI, disease-free-interval; WHO, World Health Organization; CMF:
cyclophosphamide, methotrexate and 5-fluorouracil; TAM = tamoxifen. 
Table 2 Grade III–IV WHO toxicity in 69 patients with metastatic breast cancer who
where treated with first line sequential 5-fluorouracil, epirubicin and cyclophosphamide
(FEC) and paclitaxel therapy 
Toxicity During FEC  During paclitaxel  Overall % of pts 
% of pts % of pts
Leukopenia 23 14 26 
Thrombocytopenia 2 1 2 
Anaemia 3 2 4 
Nausea and vomiting 6 2 7 
Alopecia 88 92 92 
Mucosytis 2 1 2 
Cardiac toxicity 1 0 1 
Neuropathy 0 9 9 
Flu-like symptoms–
hypersensitivity 0 1 1 
Arthralgia–myalgia 0 4 4 Response 
Response and stable disease rates following FEC alone and
following FEC and paclitaxel are detailed in Table 3. 
9 patients did not complete therapy because of treatment
refusal (1 patient), reversible heart failure (1 patient), early
death that occurred during FEC chemotherapy (1 patient),
major protocol violations (4 patients), respiratory hypersen-
sivity reaction (1 patient) and sudden death due to
cerebrovascular insufficiency during paclitaxel chemotherapy
(1 patient). These 9 patients are evaluated as treatment failures. 
At the end of the whole FEC-paclitaxel sequence, overall RR
was 65% (95% Cl = 53–76), and 7% of patients had stable disease.
Therapy was considered to have failed in 28% (95% Cl = 17–40)
of patients either because they could not be evaluated (9 patients,
13%) or because they had progressive disease (10 patients, 15%). 
Responses were observed at all sites of measurable disease,
except bone, independently of the number of sites involved (≤ 2 or
> 2). Both patients with isolated bone disease had stable disease
following the whole FEC-paclitaxel treatment. 
Of the 11 patients who achieved a CR after FEC, 9 maintained
this condition after paclitaxel and 2 became not evaluable after
paclitaxel. Of the 34 patients who had a PR after FEC, the status
remained unchanged in 28, whereas 2 achieved a CR, 2 progressed
and 2 became not evaluable after paclitaxel. Of the 17 patients
who had stable disease after FEC, 5 maintained this condition, 6
had a PR, 4 progressed and 2 became not evaluable after pacli-
taxel. The 4 patients who progressed during FEC therapy also
failed to respond to paclitaxel. 
Duration of response and of survival 
Median duration of response was 10.1 (2–33) months, median
TTP was 13.2 (range 1–32) months and median survival was 23.5
(range: 2–32) months (Figure 1). 
DISCUSSION 
In patients with MBC previously untreated with anthracycline
or taxanes, the integrated sequential FEC-paclitaxel treatment
administered as first or second line therapy produced the same or
better antitumour effect than regimens that associate an anthracy-
cline and paclitaxel, with less side effects. 
In fact, the overall antitumour effect was similar in our study
and in 3 recently published phase II studies (Pazos et al, 1999;
Sparano et al, 1999; Rischin et al, 2000) in which an anthracycline
was associated with paclitaxel. In these studies, the drug dosages
(i.e., epirubicin 75 mg m–2 or doxorubicin 50–60 mg m–2 and pacli-
taxel 175–200 mg m–2) were comparable to those used in our
sequential regimen and most (about 75%) patients were untreated
for metastatic disease. The 65% overall RR (with 16% of CR)
obtained with sequential FEC-paclitaxel compares well with the
overall RR of 52–76% (with 8–14% of CR) reported in these
studies. Median duration of response, TTP and survival (10.1, 13.2
and 23.5 months, respectively) in our study were also similar to
those in the above-mentioned studies (6.4–13.4, 6.9–7.3,
17.9–21.6 months, respectively). It should be noted that in one of
these trials (Sparano et al, 1999) efficacy was not measured on an
intention-to-treat basis. Our study and these 3 quoted studies failed
to confirm the much higher RR (94%, with 41% complete
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Table 3 Response rates after 5-fluorouracil, epirubicin, cyclophosphamide
(FEC) and after sequential FEC and paclitaxel treatment in 69 patients with
metastatic breast cancer 
Response no. of patients  After 4 FEC courses After 4 FEC + 4 
% of patients (95% Cl) paclitaxel courses 
Complete response 11 11 
16 16 
8–27 8–27 
Partial response 34 34 
49 49 
37–62 37–62 
Stable disease 17 5 
25 7 
15–36 2–16 
Progressive disease 4 10 
6 15 
2–14 7–25 
Not evaluable 3 9 
4 13 
2–11 7–22 
Cl = confidence interval. 
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Figure 1 Duration of response, of time to progression and of survival in
patients with metastatic breast cancer who were treated with sequential FEC
and paclitaxel response) reported in a previous study (Gianni et al, 1995), that,
otherwise, attained a similar duration of response, TTP and
survival. 
Overall toxic effects of treatments are not easy to compare
between studies for several reasons, including how the study was
dedicated at eliciting them, how many patients were evaluable for
side effects, and the different ways of reporting them (for example,
as a percentage of patients or of courses). 
Notwithstanding these drawbacks, overall grade III–IV haema-
tologic toxicity was reduced by sequencing FEC and paclitaxel
rather than administering an association of an anthracycline and
paclitaxel. In fact, leukopenia occurred in 26% of our patients
(with no febrile episodes) but in the 55–97% of the patients
in previous studies (with 0–14% of febrile episodes).
Thrombocytopenia and anaemia occurred in 2 and 4% of patients,
respectively, in our study and in 1–29% and 5–21% of 
patients, respectively, in the quoted studies. A 12% rate of 
grade III–IV leukopenia has been reported with the association of
anthracycline and paclitaxel in an adjuvant setting (Venturini 
et al, 2000). 
Comparing the incidence of non-haematologic side effects
among different studies is even harder because of the additional
problem of a notable degree of subjectivity entering the evalua-
tion. In our study, symptomatic heart failure occurred in one
patient and a > 20% decline in LVEF occurred in 2 other (3%)
patients during FEC therapy. Cumulatively, these events occurred
in, respectively, 2 and 10% of patients in the anthracycline-
paclitaxel association studies. Mucositis, arthralgia-myalgia 
and neuropathy occurred in 2, 4 and 9%, respectively, of our
patients. 
A puzzling question is comparing sequential FEC-paclitaxel
with regimens in which an anthracycline-containing induction
regimen has been randomly followed by a CMF-like regimen as
maintenance therapy for about 2 years. These studies (Muss et al,
1991; Falkson et al, 1998) were not analysed on an intention-to-
treat basis and randomized only patients who had a complete
response (Muss et al, 1991) or either response or stable disease
(Falkson et al, 1998). With respect to the outcomes in the control
group, maintenance therapy afforded a significantly longer TTP,
but overall survival was not increased and the associated grade
III–IV haematologic WHO toxicity was substantial. In fact, 3–8%
and 3% of patients experienced leukopenia and thrombocytopenia,
respectively, and nausea, vomiting and mucositis were also a
problem. All these events occurred in a consolidation combination
chemotherapy trial (Cocconi et al, 1999). Especially, in our
opinion, patients of maintenance trials were linked to long-lasting
intravenous therapy, while our sequential regimen was stopped
after 5–6 months. 
Further discussion of the advantages and disadvantages
of sequential FEC-paclitaxel, of their combination and of 
induction–maintenance regimens could clearly include evaluations
of quality of life (QoL), which were not carried out in this study.
We attempted to make some assessment of this aspect in a previous
study (Riccardi et al, 2000), but the data were controversial and
difficult to evaluate. The poor clinical feasibility of evaluating
QoL during and after treatment with the currently used question-
naires is strongly indicated by the very low number of studies in
which this has been carried out, especially in MBC (Batel-Copel 
et al, 1997). Efforts are being made to optimize the use of QoL
questionnaires because choosing different techniques leads to
different conclusions (Curran et al, 2000). 
From this study it appears that sequential first-line FEC-pacli-
taxel treatment offers the patients a reasonable opportunity of a
good antitumour effect while avoiding at least a number of 
untoward side effects, especially haematologic. This must be taken
into account in the overall palliative treatment of MBC, since
avoiding side effects of treatment is a means of preserving QoL. 
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